Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that preclinical data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback